Optimization and delivery of plasmid DNA for vaccination

Expert Review of Vaccines

Volumn 5, Issue 6, 2006, Pages 803-825

  Jechlinger, Wolfgang ^a,b  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b Mayrhofer & Jechlinger OEG   (Austria)

Author keywords

Bacterial backbone DNA; Bacterial ghosts; CpG motifs; DNA vaccination; Living bacterial DNA delivery systems; Minicircle DNA; Physical DNA delivery systems; Plasmid DNA; Synthetic DNA delivery vehicles; Virus like particles

Indexed keywords

B7 ANTIGEN; CASPASE 3; CD86 ANTIGEN; CHOLERA TOXIN B SUBUNIT; DNA VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS B VACCINE; HERPES SIMPLEX VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; LIVE VACCINE; LYMPHOTOXIN; OSTEOCLAST DIFFERENTIATION FACTOR; PLASMID DNA; PROTEIN BCL XL; RANTES; TRYPANOSOMA CRUZI VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; WART VIRUS VACCINE;

ANTIBIOTIC RESISTANCE; BIOSAFETY; CLINICAL TRIAL; CODON USAGE; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG POTENTIATION; DRUG PURITY; DRUG SAFETY; DRUG SYNTHESIS; EXPRESSION VECTOR; GENE EXPRESSION; GENE THERAPY; HEPATITIS B; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFECTION PREVENTION; INFLUENZA; NONHUMAN; POLYADENYLATION; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; TRYPANOSOMIASIS; VACCINE PRODUCTION; VIRUS LIKE AGENT;

ANIMALS; COMMUNICABLE DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; PLASMIDS; VACCINATION; VACCINES, DNA;

EID: 33845876613     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.5.6.803     Document Type: Review

References (195)

1. Kieny MP, Girard MP. Human vaccine research and development: an overview. Vaccine 23(50), 5705-5707 (2005).
2. Donnelly JJ, Liu MA, Ulmer JB. Antigen presentation and DNA vaccines. Am. J. Respir. Crit. Care Med. 162(4 Pt 2), S190-S193 (2000).
3. Shedlock DJ, Weiner DB. DNA vaccination: antigen presentation and the induction of immunity. J. Leukoc. Biol. 68(6), 793-806 (2000).
4. Forde GM. Rapid-response vaccines - does DNA offer a solution? Nat. Biotechnol. 23(9), 1059-1062 (2005).
5. Powell K. DNA vaccines - back in the saddle again? Nat. Biotechnol. 22(7), 799-801 (2004).
6. Lorenzen N, LaPatra SE. DNA vaccines for aquacultured fish. Rev. Sci. Tech. 24(1), 201-213 (2005).
7. Johnston SA, Talaat AM, McGuire MJ. Genetic immunization: what's in a name? Arch. Med. Res. 33(4), 325-329 (2002).
8. Liu MA, Ulmer JB. Gene-based vaccines. Mol. Ther. 1(6), 497-500 (2000).
9. Babiuk LA, Pontarollo R, Babiuk S, Loehr B, van Drunen Littel-van den Hurk S. Induction of immune responses by DNA vaccines in large animals. Vaccine 21(7-8), 649-658 (2003).
10. Manoj S, Babiuk LA, van Drunen Littelvan den Hurk S. Approaches to enhance the efficacy of DNA vaccines. Crit. Rev. Clin. Lab. Sci. 41(1), 1-39 (2004).
11. Cranenburgh RM, Hanak JA, Williams SG, Sherratt DJ. Escherichia coli strains that allow antibiotic-free plasmid selection and maintenance by repressor titration. Nucleic Acids Res. 29(5), E26 (2001). • The first report describing the operator repressor titration (ORT) system for antibiotic-free maintainance of plasmid (p)DNA.
12. Darquet AM, Cameron B, Wils P, Scherman D, Crouzet J. A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Ther. 4(12), 1341-1349. (1997). • The first report describing minicircle DNA production through site-specific recombination for gene-delivery purposes and demonstrating that minicircles improve gene-transfer efficiency in vitro.
13. Leutenegger CM, Boretti FS, Mislin CN et al. Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif. J. Virol. 74(22), 10447-10457 (2000). • The first report describing the minimalistic immunogenic defined gene expression (MIDGE) system.
14. Scheerlinck JY. Genetic adjuvants for DNA vaccines. Vaccine 19(17-19), 2647-2656 (2001). •• This review extensively describes the outcome of diverse studies using genetic adjuvants to improve and modulate the immune response induced by DNA vaccines.
15. Ferreira GN, Monteiro GA, Prazeres DM, Cabral JM. Downstream processing of plasmid DNA for gene therapy and DNA vaccine applications. Trends Biotechnol. 18(9), 380-388 (2000).
16. Patil SD, Rhodes DG, Burgess DJ. DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J. 7(1), E61-E77 (2005).
17. Brown MD, Schatzlein AG, Uchegbu IF. Gene delivery with synthetic (non viral) carriers. Int. J. Pharm. 229(1-2), 1-21 (2001).
18. Stinski M. Cytomegalovirus promoter for expression in mammalian cells. In: Gene expression systems. Fernandez J, Hoeffler J (Eds). Academic Press, CA, USA 211-233 (1999).
19. Norman JA, Hobart P, Manthorpe M, Felgner P, Wheeler C. Development of improved vectors for DNA-based immunization and other gene therapy applications. Vaccine 15(8), 801-803 (1997).
20. Lee AH, Suh YS, Sung JH, Yang SH, Sung YC. Comparison of various expression plasmids for the induction of immune response by DNA immunization. Mol. Cells 7(4), 495-501 (1997).
21. Wright A, Semyonov A, Dawes G et al. Diverse plasmid DNA vectors by directed molecular evolution of cytomegalovirus promoters. Hum. Gene Ther. 16(7), 881-892 (2005).
22. Sawicki JA, Morris RJ, Monks B, Sakai K, Miyazaki J. A composite CMV-IE enhancer/β-actin promoter is ubiquitously expressed in mouse cutaneous epithelium. Exp. Cell Res. 244(1), 367-369 (1998).
23. Furth PA, Hennighausen L, Baker C, Beatty B, Woychick R. The variability in activity of the universally expressed human cytomegalovirus immediate early gene 1 enhancer/promoter in transgenic mice. Nucleic Acids Res. 19(22), 6205-6208 (1991).
24. Harms JS, Splitter GA. Interferon-γ inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. Hum. Gene Ther. 6(10), 1291-1297 (1995).
25. Loirat D, Li Z, Mancini M et al. Muscle-specific expression of hepatitis B surface antigen: no effect on DNA-raised immune responses. Virology 260(1), 74-83 (1999).
26. Bojak A, Hammer D, Wolf H, Wagner R. Muscle specific versus ubiquitous expression of Gag-based HIV-1 DNA vaccines: a comparative analysis. Vaccine 20(15), 1975-1979 (2002).
27. Cazeaux N, Bennasser Y, Vidal PL et al. Comparative study of immune responses induced after immunization with plasmids encoding the HIV-1 Nef protein under the control of the CMV-IE or the muscle-specific desmin promoter. Vaccine 20(27-28), 3322-3331 (2002).
28. Vanniasinkam T, Reddy ST, Ertl HC. DNA immunization using a non-viral promoter. Virology 344(2), 412-420 (2006).
29. Tornoe J, Kusk P, Johansen TE, Jensen PR. Generation of a synthetic mammalian promoter library by modification of sequences spacing transcription factor binding sites. Gene 297(1-2), 21-32 (2002).
30. Garg S, Oran AE, Hon H, Jacob J. The hybrid cytomegalovirus enhancer/chicken β-actin promoter along with woodchuck hepatitis virus posttranscriptional regulatory element enhances the protective efficacy of DNA vaccines. J. Immunol. 173(1), 550-558 (2004).
31. Zinckgraf JW, Silbart LK. Modulating gene expression using DNA vaccines with different 3β-UTRs influences antibody titer, seroconversion and cytokine profiles. Vaccine 21(15), 1640-1649 (2003).
32. Ko HJ, Ko SY, Kim YJ et al. Optimization of codon usage enhances the immunogenicity of a DNA vaccine encoding mycobacterial antigen Ag85B. Infect. Immun. 73(9), 5666-5674 (2005).
33. Narum DL, Kumar S, Rogers WO et al. Codon optimization of gene fragments encoding Plasmodium falciparum merzoite proteins enhances DNA vaccine protein expression and immunogenicity in mice. Infect. Immun. 69(12), 7250-7253 (2001).
34. Deml L, Bojak A, Steck S et al. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. J. Virol. 75(22), 10991-11001 (2001).
35. Schwartz S, Campbell M, Nasioulas G et al. Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression. J. Virol. 66(12), 7176-7182 (1992).
36. zur Megede J, Chen MC, Doe B et al. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene. J. Virol. 74(6), 2628-2635 (2000).
37. Liu MA, Wahren B, Hedestam GB. DNA vaccines: recent developments and future possibilities. Hum. Gene Ther. (2006) (Epub ahead of print).
38. Calarota SA, Weiner DB. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunol. Rev. 199, 84-99 (2004). • Describes the use of genetic adjuvants to improve HIV DNA vaccines and summarizes several studies performed for this purpose.
39. Barouch DH, Santra S, Steenbeke TD et al. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J. Immunol. 161(4), 1875-1882 (1998).
40. Sin J, Kim JJ, Pachuk C, Satishchandran C, Weiner DB. DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4(+) T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo. J. Virol. 74(23), 11173-11180 (2000).
41. Applequist SE, Rollman E, Wareing MD et al. Activation of innate immunity, inflammation, and potentiation of DNA vaccination through mammalian expression of the TLR5 agonist flagellin. J. Immunol. 175(6), 3882-3891 (2005).
42. Kim TW, Hung CF, Ling M et al. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J. Clin. Invest. 112(1), 109-117 (2003).
43. Sasaki S, Amara RR, Oran AE, Smith JM, Robinson HL. Apoptosis-mediated enhancement of DNA-raised immune responses by mutant caspases. Nat. Biotechnol. 19(6), 543-547 (2001).
44. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4(4), 249-258 (2004). •• A comprehensive review describing the mode of action of CpG motifs and how they are able to trigger an immunomodulatory cascade.
45. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709-760 (2002).
46. Wagner H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv. Immunol. 73, 329-368 (1999).
47. Rankin R, Pontarollo R, Ioannou X et al. CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev. 11(5), 333-340 (2001).
48. Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature 408(6813), 740-745 (2000). • The first report showing that cellular response to CpG DNA is mediated by a Toll-like receptor (TLR)9.
49. Bauer S, Kirschning CJ, Hacker H et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl Acad. Sci. USA 98(16), 9237-9242 (2001).
50. Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374(6522), 546-549 (1995).
51. Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol. 164(2), 944-953 (2000).
52. Yamada H, Gursel I, Takeshita F et al. Effect of suppressive DNA on CpG-induced immune activation. J. Immunol. 169(10), 5590-5594 (2002).
53. Krieg AM, Wu T, Weeratna R et al. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc. Natl Acad. Sci. USA 95(21), 12631-12636 (1998).
54. Hartikka J, Sawdey M, Cornefert-Jensen F et al. An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum. Gene Ther. 7(10), 1205-1217 (1996).
55. Valera A, Perales JC, Hatzoglou M, Bosch F. Expression of the neomycin-resistance (neo) gene induces alterations in gene expression and metabolism. Hum. Gene Ther. 5(4), 449-456 (1994).
56. Schmidt T, Friehs K, Flaschel E. Structures of plasmid DNA. In: Plasmids for Therapy and Vaccination. Schleef M (Ed.). Wiley-VCH Verlag GmbH & Co. KGaA, Germany 29-43 (2001).
57. Schleef M, Schmidt T. Animal-free production of ccc-supercoiled plasmids for research and clinical applications. J. Gene Med. 6(Suppl. 1), S45-S53 (2004).
58. Schleef M, Baier R, Ealther W, Michel ML, Schmeer M. Long-term stability study and topology analysis of plasmid DNA by capillary gel electrophoresis. BioProcess (2006) (In Press).
59. Voß C, Schmidt T, Schleef M. From bulk to delivery: plasmid manufacturing and storage. In: DNA Pharmaceuticals: Formulation and Delivery in Gene Therapy, DNA vaccination and Immunotherapy. Schleef M (Ed.). Wiley-VCH Verlag GmbH & Co. KGaA, Germany 23-43 (2005).
60. Horn NA, Meek JA, Budahazi G, Marquet M. Cancer gene therapy using plasmid DNA: purification of DNA for human clinical trials. Hum. Gene Ther. 6(5), 565-573 (1995).
61. Prazeres DM, Schluep T, Cooney C. Preparative purification of supercoiled plasmid DNA using anion-exchange chromatography. J. Chromatogr. A 806(1), 31-45 (1998).
62. Ferreira GN, Prazeres DM, Cabral JM, Schleef M. Plasmid manufacturing - an overview. In: Plasmids for Therapy and Vaccination. Schleef M (Ed.). Wiley-VCH Verlag GmbH & Co. KGaA, Germany 193-236 (2001). •• A comprehensive review on plasmid manufacturing issues.
63. Best AN, Allison DP, Novelli GD. Purification of supercoiled DNA of plasmid col E1 by RPC-5 chromatography. Anal. Biochem. 114(2), 235-243 (1981).
64. Colote S, Ferraz C, Liautard JP. Analysis and purification of plasmid DNA by reversed-phase high-performance liquid chromatography. Anal. Biochem. 154(1), 15-20 (1986).
65. Ghose S, Forde GM, Slater NK. Affinity adsorption of plasmid DNA. Biotechnol. Prog. 20(3), 841-850 (2004).
66. Forde GM, Ghose S, Slater NK et al. LacO-lacI interaction in affinity adsorption of plasmid DNA. Biotechnol. Bioeng. (2006).
67. Mayrhofer P, Azimpour Tabrizi C, Walcher P et al. Immobilization of plasmid DNA in bacterial ghosts. J. Control Release 102, 725-735 (2005).
68. Wils P, Escriou V, Warnery A et al. Efficient purification of plasmid DNA for gene transfer using triple-helix affinity chromatography. Gene Ther. 4(4), 323-330 (1997).
69. Schluep T, Cooney CL. Purification of plasmids by triplex affinity interaction. Nucleic Acids Res. 26(19), 4524-4528 (1998).
70. Moreno S, Lopez-Fuertes L, Vila-Coro AJ et al. DNA immunisation with minimalistic expression constructs. Vaccine 22(13-14), 1709-1716 (2004).
71. Lopez-Fuertes L, Perez-Jimenez E, Vila-Coro AJ et al. DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. Vaccine 21(3-4), 247-257 (2002).
72. Zheng C, Juhls C, Oswald D et al. Effect of different nuclear localization sequences on the immune responses induced by a MIDGE vector encoding bovine herpes virus-1 glycoprotein D. Vaccine 24(21), 4625-4629 (2006).
73. Darquet AM, Rangara R, Kreiss P et al. Minicircle: an improved DNA molecule for in vitro and in vivo gene transfer. Gene Ther. 6(2), 209-218 (1999).
74. Kreiss P, Cameron B, Darquet AM, Scherman D, Crouzet J. Production of a new DNA vehicle for gene transfer using site-specific recombination. Appl. Microbiol. Biotechnol. 49(5), 560-567 (1998).
75. Bigger BW, Tolmachov O, Collombet JM et al. An araC-controlled bacterial cre expression system to produce DNA minicircle vectors for nuclear and mitochondrial gene therapy. J. Biol. Chem. 276(25), 23018-23027. (2001).
76. Chen ZY, He CY, Ehrhardt A, Kay MA. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol. Ther. 8(3), 495-500 (2003). • Demonstrates that minicircle DNA devoid of bacterial sequences expressed dramatically higher gene levels, compared with standard plasmid DNAs transfected.
77. Jechlinger W, Azimpour Tabrizi C, Lubitz W, Mayrhofer P. Minicircle DNA immobilized in bacterial ghosts: in vivo production of safe non-viral DNA delivery vehicles. J. Mol. Microbiol. Biotechnol. 8(4), 222-231 (2004). • Describes the complete recombination of parental plasmids in minicircles and miniplasmids and demonstrates the production of a bacterial DNA delivery vehicles self-loaded with minicircle DNA in vivo in a continuous process.
78. Chen ZY, He CY, Kay MA. Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo. Hum. Gene Ther. 16(1), 126-131 (2005). • Describes the purification of minicircle DNA based on the expression of a endonuclease and subsequent specific degradation of the parental- and miniplasmids in vivo in Escherichia coli.
79. Peachman KK, Rao M, Alving CR. Immunization with DNA through the skin. Methods 31(3), 232-242 (2003).
80. Dean HJ, Fuller D, Osorio JE. Powder and particle-mediated approaches for delivery of DNA and protein vaccines into the epidermis. Comp. Immunol. Microbiol. Infect. Dis. 26(5-6), 373-388 (2003). • A review describing the main aspects of particle bombardment.
81. McCluskie MJ, Brazolot Millan CL, Gramzinski RA et al. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol. Med. 5(5), 287-300 (1999).
82. Haynes JR, McCabe DE, Swain WF, Widera G, Fuller JT. Particle-mediated nucleic acid immunization. J. Biotechnol. 44(1-3), 37-42 (1996).
83. Tacket CO, Roy MJ, Widera G et al. Phase I safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 17(22), 2826-2829 (1999).
84. Roy MJ, Wu MS, Barr LJ et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19(7-8), 764-778 (2000).
85. Anwer K, Earle KA, Shi M et al. Synergistic effect of formulated plasmid and needle-free injection for genetic vaccines. Pharm. Res. 16(6), 889-895 (1999).
86. Gramzinski RA, Millan CL, Obaldia N, Hoffman SL, Davis HL. Immune response to a hepatitis B DNA vaccine in Aotus monkeys: a comparison of vaccine formulation, route, and method of administration. Mol. Med. 4(2), 109-118 (1998).
87. Mumper RJ, Cui Z. Genetic immunization by jet injection of targeted pDNA-coated nanoparticles. Methods 31(3), 255-262 (2003).
88. Cui Z, Baizer L, Mumper RJ. Intradermal immunization with novel plasmid DNA-coated nanoparticles via a needle-free injection device. J. Biotechnol. 102(2), 105-115 (2003).
89. Bureau MF, Gehl J, Deleuze V, Mir LM, Scherman D. Importance of association between permeabilization and electrophoretic forces for intramuscular DNA electrotransfer. Biochim. Biophys. Acta. 1474(3), 353-359 (2000).
90. Bloquel C, Fabre E, Bureau MF, Scherman D. Plasmid DNA electrotransfer for intracellular and secreted proteins expression: new methodological developments and applications. J. Gene Med. 6(Suppl. 1), S11-S23 (2004). • Describes the principles and applications of pDNA electroporation (electrotransfer).
91. Wells DJ. Gene therapy progress and prospects: electroporation and other physical methods. Gene Ther. 11(18), 1363-1369 (2004). • Provides an overview of several physical methods with a focus on electroporation.
92. Gazdhar A, Bilici M, Pierog J et al. In vivo electroporation and ubiquitin promoter - a protocol for sustained gene expression in the lung. J. Gene Med. 8(7), 910-918 (2006).
93. Smorlesi A, Papalini F, Amici A et al. Evaluation of different plasmid DNA delivery systems for immunization against HER2/neu in a transgenic murine model of mammary carcinoma. Vaccine 24(11), 1766-1775 (2006).
94. Widera G, Austin M, Rabussay D et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J. Immunol. 164(9), 4635-4640 (2000).
95. Bachy M, Boudet F, Bureau M et al. Electric pulses increase the immunogenicity of an influenza DNA vaccine injected intramuscularly in the mouse. Vaccine 19(13-14), 1688-1693 (2001).
96. Sebestyen MG, Budker VG, Budker T et al. Mechanism of plasmid delivery by hydrodynamic tail vein injection. I. Hepatocyte uptake of various molecules. J. Gene Med. 8(7), 852-873 (2006).
97. Zhang G, Budker V, Williams P, Subbotin V, Wolff JA. Efficient expression of naked DNA delivered intra-arterially to limb muscles of nonhuman primates. Hum. Gene Ther. 12(4), 427-438 (2001).
98. Taniyama Y, Tachibana K, Hiraoka K et al. Development of safe and efficient novel nonviral gene transfer using ultrasound: enhancement of transfection efficiency of naked plasmid DNA in skeletal muscle. Gene Ther. 9(6), 372-380 (2002).
99. Zeira E, Manevitch A, Khatchatouriants A et al. Femtosecond infrared laser-an efficient and safe in vivo gene delivery system for prolonged expression. Mol. Ther. 8(2), 342-350 (2003).
100. Xenariou S, Griesenbach U, Ferrari S et al. Using magnetic forces to enhance non-viral gene transfer to airway epithelium in vivo. Gene Ther. (2006).
101. Liu G, Molas M, Grossmann GA et al. Biological properties of poly-L-lysine-DNA complexes generated by cooperative binding of the polycation. J. Biol. Chem. 276(37), 34379-34387 (2001).
102. Dunlap DD, Maggi A, Soria MR, Monaco L. Nanoscopic structure of DNA condensed for gene delivery. Nucleic Acids Res. 25(15), 3095-3101 (1997).
103. Leonetti JP, Degols G, Lebleu B. Biological activity of oligonucleotide-poly(L-lysine) conjugates: mechanism of cell uptake. Bioconjug. Chem. 1(2), 149-153 (1990).
104. Boussif O, Lezoualc'h F, Zanta MA et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl Acad. Sci. USA 92(16), 7297-7301 (1995).
105. Sonawane ND, Szoka FC Jr, Verkman AS. Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. J. Biol. Chem. 278(45), 44826-44831 (2003). • Description of the 'proton-sponge effect' resulting in the high transfection efficiencies of polyethylenimine (PEI) and dendrimers.
106. Ciftci K, Levy RJ. Enhanced plasmid DNA transfection with lysosomotropic agents in cultured fibroblasts. Int. J. Pharm. 218(1-2), 81-92 (2001).
107. Zauner W, Kichler A, Schmidt W, Sinski A, Wagner E. Glycerol enhancement of ligand-polylysine/DNA transfection. Biotechniques 20(5), 905-913 (1996).
108. Lechardeur D, Sohn KJ, Haardt M et al. Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer. Gene Ther. 6(4), 482-497 (1999).
109. Brunner S, Sauer T, Carotta S et al. Cell cycle dependence of gene transfer by lipoplex, polyplex and recombinant adenovirus. Gene Ther. 7(5), 401-407 (2000).
110. Godbey WT, Wu KK, Mikos AG. Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery. Proc. Natl Acad. Sci. USA 96(9), 5177-5181 (1999).
111. Schaffer DV, Fidelman NA, Dan N, Lauffenburger DA. Vector unpacking as a potential barrier for receptor-mediated polyplex gene delivery. Biotechnol. Bioeng. 67(5), 598-606 (2000).
112. Thomas M, Klibanov AM. Non-viral gene therapy: polycation-mediated DNA delivery. Appl. Microbiol. Biotechnol. 62(1), 27-34 (2003).
113. Kircheis R, Wightman L, Wagner E. Design and gene delivery activity of modified polyethylenimines. Adv. Drug Deliv. Rev. 53(3), 341-358 (2001). •• Comprehensive review on the mechanisms of PEI mediated gene delivery and the applications of modified and unmodified PEI/DNA complexes in vivo.
114. Dash PR, Read ML, Barrett LB, Wolfert MA, Seymour LW. Factors affecting blood clearance and in vivo distribution of polyelectrolyte complexes for gene delivery. Gene Ther. 6(4), 643-650 (1999).
115. Ogris M, Brunner S, Schuller S, Kircheis R, Wagner E. PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther. 6(4), 595-605 (1999).
116. Kircheis R, Wightman L, Schreiber A et al. Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application. Gene Ther. 8(1), 28-40 (2001).
117. Zanta MA, Boussif O, Adib A, Behr JP. In vitro gene delivery to hepatocytes with galactosylated polyethylenimine. Bioconjug. Chem. 8(6), 839-844 (1997).
118. Midoux P, Mendes C, Legrand A et al. Specific gene transfer mediated by lactosylated poly-L-lysine into hepatoma cells. Nucleic Acids Res. 21(4), 871-878 (1993).
119. Hashida M, Takemura S, Nishikawa M, Takakura Y. Targeted delivery of plasmid DNA complexed with galactosylated poly(L-lysine). J. Control Release 53(1-3), 301-310 (1998).
120. Park TG, Jeong JH, Kim SW. Current status of polymeric gene delivery systems. Adv. Drug Deliv. Rev. 58(4), 467-486 (2006). •• Provides an extensive overview of the state of the art of polymeric (poly-L-lysin, PEI and others) gene delivery.
121. Mansouri S, Lavigne P, Corsi K et al. Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy. Eur. J. Pharm. Biopharm. 57(1), 1-8 (2004).
122. Dufes C, Uchegbu IF, Schatzlein AG. Dendrimers in gene delivery. Adv. Drug Deliv. Rev. 57(15), 2177-2202 (2005). •• A comprehensive review on all aspects of dendrimers in DNA delivery.
123. Johansen P, Men Y, Merkle HP, Gander B. Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur. J. Pharm. Biopharm. 50(1), 129-146 (2000).
124. Men Y, Gander B, Merkle HP, Corradin G. Induction of sustained and elevated immune responses to weakly immunogenic synthetic malarial peptides by encapsulation in biodegradable polymer microspheres. Vaccine 14(15), 1442-1450 (1996).
125. Walter E, Dreher D, Kok M et al. Hydrophilic poly(DL-lactide-co- glycolide) microspheres for the delivery of DNA to human-derived macrophages and dendritic cells. J. Control Release 76(1-2), 149-168 (2001).
126. Tamber H, Johansen P, Merkle HP, Gander B. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv. Drug Deliv. Rev. 57(3), 357-376 (2005).
127. Ando S, Putnam D, Pack DW, Langer R. PLGA microspheres containing plasmid DNA: preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization. J. Pharm. Sci. 88(1), 126-130 (1999).
128. Thiele L, Merkle HP, Walter E. Phagocytosis and phagosomal fate of surface-modified microparticles in dendritic cells and macrophages. Pharm. Res. 20(2), 221-228 (2003).
129. Jilek S, Merkle HP, Walter E. DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells. Adv. Drug Deliv. Rev. 57(3), 377-390 (2005). • Reviews the advantages of associating DNA to microparticles in order to increase the potency of DNA vaccination in vivo.
130. Howard KA, Li XW, Somavarapu S et al. Formulation of a microparticle carrier for oral polyplex-based DNA vaccines. Biochim. Biophys. Acta. 1674(2), 149-157 (2004).
131. Tranchant I, Thompson B, Nicolazzi C, Mignet N, Scherman D. Physicochemical optimisation of plasmid delivery by cationic lipids. J. Gene Med. 6(Suppl. 1), S24-D35 (2004). • Describes the use and the optimization of cationic lipid-mediated gene delivery.
132. Gregoriadis G, Bacon A, Caparros-Wanderley W, McCormack B. A role for liposomes in genetic vaccination. Vaccine 20(Suppl. 5), B1-B9 (2002).
133. Zhdanov RI, Podobed OV, Vlassov VV. Cationic lipid-DNA complexes-lipoplexes-for gene transfer and therapy. Bioelectrochemistry 58(1), 53-64 (2002).
134. Radler JO, Koltover I, Salditt T, Safinya CR. Structure of DNA-cationic liposome complexes: DNA intercalation in multilamellar membranes in distinct interhelical packing regimes. Science 275(5301), 810-814 (1997).
135. Koltover I, Salditt T, Radler JO, Safinya CR. An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery. Science 281(5373), 78-81 (1998).
136. Zhou X, Huang L. DNA transfection mediated by cationic liposomes containing lipopolylysine: characterization and mechanism of action. Biochim. Biophys. Acta. 1189(2), 195-203 (1994).
137. Mounkes LC, Zhong W, Cipres-Palacin G, Heath TD, Debs RJ. Proteoglycans mediate cationic liposome-DNA complex-based gene delivery in vitro and in vivo. J. Biol. Chem. 273(40), 26164-26170 (1998).
138. Friend DS, Papahadjopoulos D, Debs RJ. Endocytosis and intracellular processing accompanying transfection mediated by cationic liposomes. Biochim. Biophys. Acta. 1278(1), 41-50 (1996).
139. Xu Y, Szoka FC Jr. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 35(18), 5616-5623 (1996).
140. Hafez IM, Maurer N, Cullis PR. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther. 8(15), 1188-1196 (2001).
141. Zuidam NJ, Hirsch-Lerner D, Margulies S, Barenholz Y. Lamellarity of cationic liposomes and mode of preparation of lipoplexes affect transfection efficiency. Biochim. Biophys. Acta. 1419(2), 207-220 (1999).
142. Maurer N, Mori A, Palmer L et al. Lipid-based systems for the intracellular delivery of genetic drugs. Mol. Membr. Biol. 16(1), 129-140 (1999).
143. Dass CR. Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection. J. Mol. Med. 82(9), 579-591 (2004).
144. Anwer K, Kao G, Proctor B, Rolland A, Sullivan S. Optimization of cationic lipid/DNA complexes for systemic gene transfer to tumor lesions. J. Drug Target 8(2), 125-135 (2000).
145. Nicolazzi C, Mignet N, de la Figuera N et al. Anionic polyethyleneglycol lipids added to cationic lipoplexes increase their plasmatic circulation time. J. Control Release 88(3), 429-443 (2003).
146. Hofland HE, Masson C, Iginla S et al. Folate-targeted gene transfer in vivo. Mol. Ther. 5(6), 739-744 (2002).
147. Hattori Y, Kawakami S, Lu Y et al. Enhanced DNA vaccine potency by mannosylated lipoplex after intraperitoneal administration. J. Gene Med. 8(7), 824-834 (2006).
148. Mandic A, Vujkov T. Human papillomavirus vaccine as a new way of preventing cervical cancer: a dream or the future? Ann. Oncol. 15(2), 197-200 (2004).
149. Young KR, McBurney SP, Karkhanis LU, Ross TM. Virus-like particles: designing an effective AIDS vaccine. Methods 40(1), 98-117 (2006).
150. Ulrich R, Nassal M, Meisel H, Kruger DH. Core particles of hepatitis B virus as carrier for foreign epitopes. Adv. Virus Res. 50, 141-182 (1998).
151. Touze A, Coursaget P. In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res. 26(5), 1317-1323 (1998). • One of the first reports describing the use of virus-like particles for the delivery of pDNA.
152. Clark B, Caparros-Wanderley W, Musselwhite G, Kotecha M, Griffin BE. Immunity against both polyomavirus VP1 and a transgene product induced following intranasal delivery of VP1 pseudocapsid-DNA complexes. J. Gen. Virol. 82(Pt 11), 2791-2797 (2001).
153. Takamura S, Niikura M, Li TC et al. DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration. Gene Ther. 11(7), 628-635 (2004).
154. Zhang H, Fayad R, Wang X, Quinn D, Qiao L. Human immunodeficiency virus type 1 gag-specific mucosal immunity after oral immunization with papillomavirus pseudoviruses encoding gag. J. Virol. 78(19), 10249-10257 (2004).
155. Schoen C, Stritzker J, Goebel W, Pilgrim S. Bacteria as DNA vaccine carriers for genetic immunization. Int. J. Med. Microbiol. 294(5), 319-335 (2004). •• Reviews extensively the mechanisms of pDNA delivery by living bacteria and describes the outcome of the numerous studies performed for this purpose.
156. Guimaraes VD, Gabriel JE, Lefevre F et al. Internalin-expressing Lactococcus lactis is able to invade small intestine of guinea pigs and deliver DNA into mammalian epithelial cells. Microbes Infect. 7(5-6), 836-844 (2005).
157. Cossart P, Sansonetti PJ. Bacterial invasion: the paradigms of enteroinvasive pathogens. Science 304(5668), 242-248 (2004).
158. Weiss S, Krusch S. Bacteria-mediated transfer of eukaryotic expression plasmids into mammalian host cells. Biol. Chem. 382(4), 533-541 (2001).
159. Dietrich G, Bubert A, Gentschev I et al. Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes. Nat. Biotechnol. 16(2), 181-185 (1998). • The first report of the construction and use of self-destructing live bacteria for pDNA delivery.
160. Pilgrim S, Stritzker J, Schoen C et al. Bactofection of mammalian cells by Listeria monocytogenes: improvement and mechanism of DNA delivery. Gene Ther. 10(24), 2036-2045 (2003).
161. Xu F, Ulmer JB. Attenuated salmonella and Shigella as carriers for DNA vaccines. J. Drug Target 11(8-10), 481-488 (2003).
162. Shata MT, Hone DM. Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8(+) T cells and antiviral protective immunity. J. Virol. 75(20), 9665-9670 (2001).
163. Sandman K, Pereira SL, Reeve JN. Diversity of prokaryotic chromosomal proteins and the origin of the nucleosome. Cell. Mol. Life Sci. 54(12), 1350-1364 (1998).
164. Li L, Fang W, Li J et al. Oral DNA vaccination with the polyprotein gene of infectious bursal disease virus (IBDV) delivered by attenuated Salmonella elicits protective immune responses in chickens. Vaccine (2006).
165. Vecino WH, Quanquin NM, Martinez-Sobrido L et al. Mucosal immunization with attenuated Shigella flexneri harboring an influenza hemagglutinin DNA vaccine protects mice against a lethal influenza challenge. Virology 325(2), 192-199 (2004).
166. Du A, Wang S. Efficacy of a DNA vaccine delivered in attenuated Salmonella typhimurium against Eimeria tenella infection in chickens. Int. J. Parasitol. 35(7), 777-785 (2005).
167. Vassaux G, Nitcheu J, Jezzard S, Lemoine NR. Bacterial gene therapy strategies. J. Pathol. 208(2), 290-298 (2006).
168. Miki K, Nagata T, Tanaka T et al. Induction of protective cellular
169. Yu YA, Shabahang S, Timiryasova TM et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat. Biotechnol. 22(3), 313-320 (2004).
170. Garmory HS, Leckenby MW, Griffin KF et al. Antibiotic-free plasmid stabilization by operator-repressor titration for vaccine delivery by using live Salmonella enterica Serovar typhimurium. Infect. Immun. 73(4), 2005-2011 (2005).
171. Spreng S, Viret JF. Plasmid maintenance systems suitable for GMO-based bacterial vaccines. Vaccine 23(17-18), 2060-2065 (2005).
172. Szostak MP, Hensel A, Eko FO et al. Bacterial ghosts: non-living candidate vaccines. J. Biotechnol. 44(1-3), 161-170 (1996).
173. Mayr UB, Walcher P, Azimpour C et al. Bacterial ghosts as antigen delivery vehicles. Adv. Drug Deliv. Rev. 57(9), 1381-1391 (2005).
174. Walcher P, Mayr UB, Azimpour-Tabrizi C et al. Antigen discovery and delivery of subunit vaccines by nonliving bacterial ghost vectors. Expert Rev. Vaccines 3(6), 681-691 (2004). •• Describes the bacterial ghost technology with a focus on the delivery of pDNA or heterologous antigens.
175. Paukner S, Stiedl T, Kudela P et al. Bacterial ghosts as a novel advanced targeting system for drug and DNA delivery. Expert Opin. Drug Deliv. 3(1), 11-22 (2006).
176. Kudela P, Paukner S, Mayr UB et al. Bacterial ghosts as novel efficient targeting vehicles for DNA delivery to the human monocyte-derived dendritic cells. J. Immunother. 28(2), 136-143 (2005).
177. Paukner S, Kudela P, Kohl G et al. DNA-loaded bacterial ghosts efficiently mediate reporter gene transfer and expression in macrophages. Mol. Ther. 11(2), 215-223 (2005). • Describes that macrophages can be efficiently transfected with bacterial ghosts (BGs) packed with pDNA.
178. Ebensen T, Paukner S, Link C et al. Bacterial ghosts are an efficient delivery system for DNA vaccines. J. Immunol. 172(11), 6858-6865 (2004). • Demonstrates that BGs loaded with pDNA transfect antigen presenting cells efficiently and enable the elicitation of specific humoral and cellular immune responses against an encoded antigen in mice.
179. McMichael AJ, Hanke T. HIV vaccines 1983-2003. Nat. Med. 9(7), 874-880 (2003).
180. Sin JI, Kim JJ, Ugen KE et al. Enhancement of protective humoral (Th2) and cell-mediated (Th1) immune responses against herpes simplex virus-2 through co-delivery of granulocyte-macrophage colony-stimulating factor expression cassettes. Eur. J. Immunol. 28(11), 3530-3540 (1998).
181. Kim JJ, Trivedi NN, Nottingham LK et al. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur. J. Immunol. 28(3), 1089-1103 (1998).
182. Chow YH, Chiang BL, Lee YL et al. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J. Immunol. 160(3), 1320-1329 (1998).
183. Barouch DH, Craiu A, Kuroda MJ et al. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc. Natl Acad. Sci. USA 97(8), 4192-4197 (2000).
184. Xin KQ, Hamajima K, Sasaki S et al. IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. Vaccine 17(7-8), 858-866 (1999).
185. Larsen DL, Dybdahl-Sissoko N, McGregor MW et al. Coadministration of DNA encoding interleukin-6 and hemagglutinin confers protection from influenza virus challenge in mice. J. Virol. 72(2), 1704-1708 (1998).
186. Sin JI, Kim JJ, Boyer JD et al. In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. J. Virol. 73(1), 501-509 (1999).
187. Eo SK, Lee S, Kumaraguru U, Rouse BT. Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands. Vaccine 19(32), 4685-4693 (2001).
188. + T-cell response by DNA and viral vector vaccination. J. Immunol. 171(12), 6344-6348 (2003).
189. Flo J, Tisminetzky S, Baralle F. Modulation of the immune response to DNA vaccine by co-delivery of costimulatory molecules. Immunology 100(2), 259-267 (2000).
190. Sin JI, Kim J, Dang K et al. LFA-3 plasmid DNA enhances Ag-specific humoral- and cellular-mediated protective immunity against herpes simplex virus-2 in vivo: involvement of CD4+ T cells in protection. Cell. Immunol. 203(1), 19-28 (2000).
191. + cytotoxic responses when coadministered intradermally with a DNA vaccine. Clin. Diagn. Lab. Immunol. 11(4), 711-719 (2004).
192. EMEA: note for guidance on the quality, preclinical and clinical aspects of gene transfer. London (2001). www.emea.eu.int/pdfs/human/bwp/308899en.pdf
193. FDA: points to consider on plasmid DNA vaccines for preventive infectious disease. Rockville, MD, USA (1996). www.fda.gov/CBER/gdIns/plasmid.pdf
194. FDA: guidance for human somatic cell therapy and gene therapy. Rockville, MD, USA (1998). www.fda.gov/Cber/gdIns/somgene.pdf
195. The Journal of Gene Medicine (2004). Gene Therapy Clinical Trials. www.wiley.co.uk/genetherapy/clinical/